Researchers developed a probiotic-inspired drug delivery system targeting the gut–brain axis. In Parkinson’s mouse models, it ...
I would like to start a regular segment where I explain the latest findings for therapists!For our momentous first ...
A conductance-based computer model of the Parkinsonian brain circuit shows that deep brain stimulation and rhythmic visual ...
A 30-year innovation has arrived in Parkinson's disease treatment. The US FDA has approved AbbVie's new drug, 'Juvmo.' The ...
A multimodal imaging and voice-analysis study of early Parkinson's disease reveals that speech impairment arises from dopaminergic loss and striatal connectivity disruption in men but primarily ...
The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically significant improvements in secondary endpoints of ON time without ...
CHARLOTTESVILLE, Va. (WSET) — A new treatment for Parkinson’s disease developed from decades of research at the University of Virginia has received approval from the U.S. Food and Drug Administration.
Alan Alda is in a place of acceptance when it comes to living with Parkinson’s disease. “I can’t wish it away. I can’t hope for a better future. I gotta accept what is,” the 90-year-old M*A*S*H alum ...
CLEVELAND (WJW) — The U.S. Food and Drug Administration Monday approved a new first-of-its-kind treatment for adults living with Parkinson’s disease. Cleveland Clinic Lerner College of Medicine ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control. AbbVie may have struck out with the high-profile ...
Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results